Intratumoral IL-12
a novel approach to cancer immunotherapy treatments

Tavokinogene Telseplasmid “TAVO”

Taking the fight directly to the tumor 
Through the intratumoral administration of IL-12, our lead product candidate, TAVO, may stimulate a safe but powerful systemic immune response leading to an innovative and potentially transformative therapy option for the treatment of cancer.

LEARN MORE

IN THE CLINIC

EXPLORE OUR TECHNOLOGY

SPOTLIGHT ARTICLE

OncoSec Is Hot on Cancer’s Trail – Literally

Arming the Immune System to Fight Cancer

CLINICAL PIPELINE

Pipeline
Our core technology platform continues to advance through clinical trials for various cancers.

LEARN MORE

TECHNOLOGY

Technology
The Intratumoral IL-12 platform is designed to boost the immune system to recognize and attack tumors.

LEARN MORE

COLLABORATORS

Collaborators
OncoSec continues to establish relationships with industry leaders to further advance our research.

LEARN MORE

Clinical trials of today may power
the medical advances of tomorrow.

LEARN MORE ABOUT OUR CURRENT CLINICAL TRIALS

Advanced MelanomaTriple Negative Breast Cancer